Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biogen Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

58 comunicati stampa

Guarda tutti i comunicati
05/03/2026
Biotecnologia
Medicina Salute Benessere
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
04/03/2026
Biotecnologia
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
11/02/2026
Biotecnologia
Biogen Announces Board Chair Transition
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
04/02/2026
Biotecnologia
Medicina Salute Benessere
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
28/01/2026
Biotecnologia
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
22/12/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
05/12/2025
Biotecnologia
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/11/2025
Biotecnologia
Medicina Salute Benessere
Management/Organizzazione Aziendale
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0